CommercialDocumentationHigh impact
New Documentation Requirements for Incretin Mimetics
CareFirst BlueCross BlueShield·Family Medicine, Internal Medicine, Endocrinology +1 more·Pharmacy
Effective date
Jan 1, 2024
We identified it
Jun 20, 2026
Summary
Effective January 1, 2024, CareFirst BlueCross BlueShield will require clinical documentation supporting a type 2 diabetes diagnosis for coverage of incretin mimetics including OZEMPIC, MOUNJARO, TRULICITY, VICTOZA, RYBELSUS, BYDUREON BCISE, and BYETTA. The insurer is implementing automated verification using diagnosis codes from medical claims history to streamline prior authorization.
Action Required
By January 1, 2024: Providers must ensure accurate ICD-10 coding for type 2 diabetes mellitus on all medical claims for patients prescribed incretin mimetics (OZEMPIC, MOUNJARO, TRULICITY, VICTOZA, RYBELSUS, BYDUREON BCISE, BYETTA). Billing team must update encounter forms and EMR templates to remind providers to document and code diabetes diagnoses accurately. Contact CVS Caremark at 855-582-2038 for pharmacy prior authorization questions.